Which of the following best describes the action of SGLT2 inhibitors?

SGLT2 inhibitors, such as canagliflozin, dapagliflozin, and empagliflozin, primarily function by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules. This action leads to an increase in urinary glucose excretion by preventing the reabsorption of glucose from the renal filtrate back into the bloodstream. As a result, excess glucose is expelled through urine, which also contributes to lowering blood glucose levels in patients with conditions like type 2 diabetes.

While SGLT2 inhibitors do not directly impact hepatic glucose production, facilitate glucose absorption in the intestines, or enhance insulin secretion, their mechanism of promoting urinary glucose excretion has significant implications for glycemic control, weight loss, and cardiovascular benefits for individuals with diabetes.